- Repligen Corporation (NASDAQ:RGEN) entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocessing market.
- Through this agreement, Repligen will assume responsibility for the commercialization of Culpeo and the development of future products and technologies in partnership with DRS Daylight Solutions.
- Also read: Catalent-Repligen Merger ‘Seems Unlikely,’ This Analyst Says.
- Both companies will focus on expanding the portfolio of Quantum Cascade Laser mid-IR (QCL-IR) based solutions and integrating these solutions into Repligen Chromatography and Filtration systems to expand their presence in the Process Analytics Technology (PAT) segment.
- Daylight’s patented QCL-IR technology measures higher-order protein and nucleic acid structure, facilitating the measurement of protein aggregation, concentration, nucleic acid content, and other critical attributes in biological manufacturing processes.
- DRS Daylight Solutions entered the bioprocessing market in 2018 with its ground-breaking Culpeo instrument.
- Price Action: RGEN shares are down 5.43% at $212.97 on the last check Tuesday.
TransCode Therapeutics And 2 Other Stocks Under $5 Insiders Are Aggressively Buying
The Dow Jones closed higher by over 140 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
